Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-16T01:25:32.575Z Has data issue: false hasContentIssue false

Zolpidem abuse: About a case

Published online by Cambridge University Press:  23 March 2020

R. Sellami*
Affiliation:
Hedi Chaker University Hospital, Psychiatry A, Sfax, Tunisia
N. Messedi
Affiliation:
Hedi Chaker University Hospital, Psychiatry A, Sfax, Tunisia
I. Feki
Affiliation:
Hedi Chaker University Hospital, Psychiatry A, Sfax, Tunisia
I. Baati
Affiliation:
Hedi Chaker University Hospital, Psychiatry A, Sfax, Tunisia
A. Zahaf
Affiliation:
ATUPRET, Drug Abuse Prevention Center, Sfax, Tunisia
J. Masmoudi
Affiliation:
Hedi Chaker University Hospital, Psychiatry A, Sfax, Tunisia
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

Zolpidem is a non-benzodiazepine hypnotic drug for treatment of insomnia and is generally believed that is a safe medication. Therefore has been introduced as a lower potential agent for dependency and abusive effects however its safety and dependence potential are of great concern.

Case report

A 63 years old male patient had consulted a general physician in January 2015 for his insomnia. He started on zolpidem 10 mg at bedtime. Over the next few months he had gradually increased the dose as he found the prescribed dose to be having no significant effect. After abrupt discontinuation of zolpidem, he presented to a center for drug users “AIDE ET ECOUTE” with severe anxiety, impatience, loss of energy, insomnia, irritability, headaches, and increased craving for higher dosage of zolpidem. There was no history of any other substance abuse and he was diagnosed simultaneously a case of zolpidem dependence and major depressive disorder.

Conclusions

Zolpidem has a potency to be abused with high risk of dependency and withdrawal syndromes particularly among elderly patients with comorbid anxiety and depressive disorders.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV71
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.